Megace

Megestrol Acetate, the active ingredient in Megace, is a progestin presented as an oral tablet for oral use. It is employed to stimulate appetite in patients with severe weight loss and to treat certain hormone‑sensitive cancers.

GNH USA supplies Megace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand, with a distribution network that ensures timely delivery across Europe, Asia, Africa and the Americas.

Megace is used in oncology and HIV‑related cachexia to address metabolic and hormonal pathways that cause severe weight loss. - Cachexia (AIDS or cancer): Improves appetite and promotes weight gain. - Advanced breast cancer: Reduces tumor progression in hormone‑responsive disease. - Endometrial cancer: Provides antineoplastic activity in progesterone‑sensitive tumors.

Megace may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness, often transient. - Edema: peripheral swelling due to fluid retention. - Weight gain: paradoxical increase, sometimes from fluid accumulation.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Adrenal suppression: reduced endogenous cortisol production, especially with abrupt discontinuation. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hyperglycemia: significant rise in blood glucose, particularly in diabetic patients.

Before initiating therapy, clinicians should assess baseline risk factors and monitor patients regularly. - Monitor weight: track changes to evaluate efficacy and detect fluid overload. - Assess blood glucose: hyperglycemia may develop, especially in diabetic patients. - Evaluate lipid profile: potential increases in cholesterol and triglycerides. - Check for thrombotic risk: consider prophylaxis in high‑risk individuals. - Review hepatic function: liver enzymes may rise during therapy. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Megace can interact with several drug classes; careful review is recommended.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, increasing bleeding risk. - CYP3A4 inducers (rifampin, phenytoin): may reduce megestrol levels, diminishing efficacy. - Antidiabetic agents: may exacerbate hyperglycemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: additive glucocorticoid effects may increase fluid retention. - Hormonal contraceptives: may alter contraceptive efficacy. - Digoxin: possible increase in serum digoxin concentrations.